Back to Search Start Over

Control of intraocular pressure elevations after argon laser trabeculoplasty

Authors :
John A. Campagna
Erin A. Doe
Monte S. Dirks
Scott D. Barnes
Source :
Ophthalmology. 106:2033-2037
Publication Year :
1999
Publisher :
Elsevier BV, 1999.

Abstract

Objective To determine whether brimonidine 0.2% can control intraocular pressure (IOP) spikes as well as apraclonidine 1.0% can in those patients undergoing argon laser trabeculoplasty (ALT). Design Prospective, randomized, double-masked, clinical trial. Participants A total of 56 eyes of 41 patients with open-angle glaucoma or ocular hypertension were entered in the study; 46 eyes of 41 patients were eventually used for the final analysis. Intervention Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1.0% before and after 360° ALT. Both patient and physician were masked as to which agent each patient received. Main outcome measures Intraocular pressure measurements were recorded before surgery and at 1, 2, and 4 hours after surgery. The difference between the preoperative IOP (baseline) and the highest recorded postoperative IOP was recorded as the maximum IOP change. The mean of the maximum IOP change for each group was analyzed using a two-sample, one-tailed t test. Results The mean of the maximum IOP change in the brimonidine 0.2% group was −2.6 ± 3.6 mmHg, and the mean for the apraclonidine 1.0% group was −2.3 ± 3.7 mmHg ( P = 0.8). No patient had a pressure spike greater than 10 mmHg. Conclusions Brimonidine 0.2% appears to be as effective as apraclonidine 1.0% in preventing IOP spikes after argon laser trabeculoplasty.

Details

ISSN :
01616420
Volume :
106
Database :
OpenAIRE
Journal :
Ophthalmology
Accession number :
edsair.doi...........91f7c9a35c1a36937f93cda9b130d2bf
Full Text :
https://doi.org/10.1016/s0161-6420(99)90420-7